Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Pharmos(PARS) -- Ignore unavailable to you. Want to Upgrade?

To: David Israel-Rosen who wrote (671)	5/2/1998 5:32:00 PM
From: InvestorLady	Read Replies (2) \| Respond to of 1491

While I would like this to be true since I am a shareholder, the exhubberance you are displaying is a red flag. Some of what you have said is questionable: Cutting down office visits means cutting into their income. You sure this is such a great selling point? You are assuming the BLIND study will be favorable. That is not a given. What are indications so far for Level II trials? (Forgive me for not knowing this already. Looking forward to a reply, Lady

To: David Israel-Rosen who wrote (671)	5/3/1998 6:06:00 PM
From: LLLefty	Read Replies (3) \| Respond to of 1491

Firstly, in the interest of credibility, please clarify your comment that 500 ophthamologists do 95 percent of the 1,000,000 cataract surgeries annually in US. If I read you right, that means the 500 average 1900 surgeries a year. Given one hour for each, that means they are in the operating room almost 8 hours day, five days a week. That doesn't give them much time for golf, much less time to see their same patients for pre-surgery exam and the conventional three follow-up visits. Secondly, your incivility to Investor Lady was uncalled for. There is room for all reasoned views, pro or con on Pharmos. After all, if our stock (I'm a shareholder as well) were such a hot item on the cusp of rising four, five or ten fold, are we the only ones who know it?

To: David Israel-Rosen who wrote (671)	5/3/1998 9:36:00 PM
From: arnie h	Read Replies (2) \| Respond to of 1491

David: With all due respect, I'm wondering why you use 42M shares to get the earnings per share? We already have committed to quite a few shares beyond this level and as a group voted to increase the total to 60M.Based on past experience; I would guess all 60M will be thrown into the pot, either to raise more money or for stock options. In addition, my experience tells me we'll be asked to approve some more. I would note I've probably been in PARS longer than anyone else on this thread. The HU211 trial is puzzling to me since most pharmaceutical companies would conduct trials for this kind of trial in a major city in the US where there are lots of motorcyclists and car accidents. I would note it has taken a long time to recruit 69 patients and will probably be until next year before 90 are reached. I think you're wise to not count HU211 in your estimates. Nonetheless, I'm optimistic that a major company will join up. If and when that happens the price will take off. We've had lots of input on the thread to this effect but so far, it's been warm air. Until then, we're at the pleasure of the Elliot group. I would note the stock is now some 25% off it's recent high. As I pointed out in my last missive when I noted the historically high short sales, a buying opportunity would be presenting itself; and it has. (Yes, I did pick up a bit more). Hopefully, it won't drop below $2. Have a good week, Arnie